Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 257

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 257
---
. 8 to approve the name change of NLS. •Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •Proposal No. 11 to approve the composition of the new senior management following the Merger. •Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •Proposal No. 12.2 to approve the compensation for the executive officers. Recommendation of the NLS Board The NLS Board has unanimously determined that the each of the Proposals is fair to and in the best interests of NLS and its shareholders; has unanimously approved each of the Proposals; and unanimously recommends that shareholders vote “FOR” each of the Proposals. 104 Record Date; Outstanding Shares; Shareholders Entitled to Vote As of August28, 2025, NLS has a share capital of CHF 178,738.14 divided into 4,908,034 NLS Common Shares, and 1,249,904 NLS Preferred Shares, par value of CHF 0.03 each per the Commercial Register of Zurich under Swiss Law. Additionally, as of August28, 2025, NLS has issued 606,452 Preferred Participation Certificates as of the date of this proxy statement/prospectus. Of the aforementioned number of shares, as of August28, 2025, NLS holds 655,977 NLS Common Shares and 23,254 Preferred Participation Certificates held in the Company’s treasury are considered treasury shares per Swiss corporate law, which are therefore not entitled to a vote at the NLS Meeting. For more information about treasury shares under Swiss law, please see “ Comparison of Shareholders’ Rights and Corporate Governance — Summary of Material Differences Between the Rights of Kadimastem Shareholders and NL Shareholders — Rights of NLS Pharmaceutics shareholders — Treasury Shares.” The aforementioned treasury shares have never been issued to any third party or reacquired, and have been held by the Company from inception. Accordingly, they do not meet the U.S. GAAP definition of treasury stock because no reacquisition transaction has occurred. For U.S. GAAP purposes, these shares are classified as issued, but not outstanding and are excluded from outstanding share counts in our financial statements elsewhere in this proxy statement/prospectus and from the calculation of basic and diluted earnings per share under U.S. GAAP. Each NLS Common Share and NLS Preferred Share entitles its holder to one vote